About this Journal Submit a Manuscript Table of Contents
Evidence-based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 391752, 10 pages
Original Article

Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide

1Department of Zoology, University of Kalyani, Kalyani-741235, India
2Boiron Lab, 69110 Sainte-Foy-Les-Lyon, France

Received 4 January 2008; Accepted 19 December 2008

Copyright © 2011 Pathikrit Banerjee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The present study was undertaken to examine if microdoses of ultra-high diluted arsenic trioxide (a potentized homeopathic remedy, Arsenicum Album 200C, diluted 10-400 times) have hepatoprotective potentials in mice subjected to repeated injections of arsenic trioxide. Arsenic intoxicated mice were divided into: (i) those receiving Arsenicum Album-200C daily, (ii) those receiving the same dose of diluted succussed alcohol (Alc 200C) and (iii) another group receiving neither drug nor succussed alcohol. Two other control groups were also maintained: one fed normal diet only and the other receiving normal diet and Alc-200C. Toxicity biomarkers like aspartate and alanine aminotransferases, glutathione reductase, catalase, succinate dehydrogenase, superoxide dismutase and reduced glutathione contents were periodically assayed keeping the observer “blinded”. Additionally, electron microscopic studies and gelatin zymography for matrix metalloproteinases of liver tissues were made at day 90 and 120. Blood glucose, hemoglobin, estradiol and testosterone contents were also studied. Compared to controls, Arsenicum Album-200C fed mice showed positive modulations of all parameters studied, thereby providing evidence of protective potentials of the homeopathic drug against chronic arsenic poisoning.

1. Introduction

Microdoses of highly diluted arsenic trioxide (As2O3 10−400) was chosen to validate its ameliorative potential against repeated arsenic intoxication employing acceptable toxicity biomarkers including specific hepato-toxicity denoting protocols. Some of these biomarkers were chosen because they reflected degree of hepatotoxicity, directly or indirectly being influenced by the extent of toxicity caused by arsenic poisoning. Further, tissue damage and necrosis, often inflicted as a result of arsenic poisoning, largely contribute to improper liver function, that in turn, may cause hepatotoxicity. In view of this, liver function tests, which include the assay of enzymes like AST and ALT, were performed. These tests can throw light on the extent of liver malfunctioning and tissue damage in arsenic intoxicated mice. Therefore, positive modulation of these parameters, if any, achieved by the administration of the remedy, can be significant and supportive of its hepato-protective potential.

Inorganic arsenic (iAs) acts as a tumor-promoting agent by inducing a rapid burst of reactive oxygen species (ROS) in mammalian cells, resulting in oxidative stress [1, 2] and carcinogenesis in man [3]. Cooperative defense systems that protect the body from free radical damage include the anti-oxidant enzymes [(superoxide dismutase (SOD), catalase (CAT) and indirectly glutathione reductase (GRD) and also GSH)] and nutrients. The study of these anti-oxidant enzymes was therefore considered very pertinent. Succinate dehydrogenase, an enzyme of the inner mitochondrial membrane is concerned with energy generation and respiration; hence is essential for cell survival. This parameter was therefore also included in this study. The hematological parameters like blood glucose, hemoglobin and hormonal studies were performed since they depict the physiological status of the body. Additionally, scanning and transmission electron microscopic analyses and gelatin zymography for analyzing expression pattern of matrix metalloproteinases (MMPs) were performed at day 90 and 120.

2. Materials

2.1. Animals

Thirty-six healthy adult Swiss albino mice (Mus musculus) of both sexes (30–40 g) served as materials for each series, six sacrificed at each fixation interval. All animal experiments were performed based on animal ethics guidelines of Institutional Animal Ethics Committee, University of Kalyani, under the supervision of Animal Welfare Committee.

2.2. Experimental Design

Mice were randomized and sub-divided into the following sub-sets.

2.3. Arsenic Intoxicated and Drug Fed Series

In all groups, injection (intraperitoneal) with 0.016% As2O3 solution (aqueous) at the rate of 1 mL/100 g body weight was performed at an interval of 7 days (Gr-1) and sacrificed at 7, 15, 30, 60, 90 and 120 days, respectively, for all groups.

A sub-group was fed Ars Alb-200C (Gr-2) once daily till sacrificed, which comprised the intoxicated drug fed series. Another sub-group (Gr-3) was fed Alc 200C. Potentized Ars Alb-200C was procured from Boiron Laboratory, Lyon, France, as also the placebo (Alc-200 C), prepared with 70% ethanol.

2.4. Control Series

A group of healthy mice was maintained on normal low protein diet (normal control—Gr -4). Another group of healthy mice were fed diluted succussed alcohol (Alc-200 C) at the same rate as that of As203, because the “vehicle" of the homeopathic remedy was ethyl alcohol (alcohol control Gr-5).

Another group of mice was injected 0.016% As203 every 7th day and fed Alc-200 C (intoxicated control) till they were sacrificed, to learn about modulated effect, if any, induced by ethyl alcohol on arsenic intoxicated mice.

3. Methods

3.1. Preparation of Tissue Homogenates

Liver and spleen tissues were homogenized in phosphate buffer saline (pH 7.4) and centrifuged at 5000 g for 60 min. The supernatant was used for assay of the marker enzymes (glutathione reductase, superoxide dismutase, catalase and succinate dehydrogenase), reduced glutathione, aspartate aminotransferase, alanine aminotransferase and protein estimation.

3.2. Biochemical Analysis

The tissue homogenate was used for the assessment of AST and ALT [4], reduced glutathione content [5], catalase [6], SOD [7], SDH [8], GRD [9, 10] and protein [11].

3.3. Pathological Parameters

Blood glucose content was assayed by the GOD-POD End point Colorimetric assay kit supplied by Span Diagnostics Limited, Baroda (Code-B0112), India.

Hemoglobin content was determined by Sahli's method with the help of a hemometer (Marienfield, Germany).

Serum estradiol and testosterone content was assayed by using the appropriate diagnostic kit (EQUPAR srl, Saronno, Italy) with the aid of an ELISA Reader (ELDEX 3.8, USA) at 450 nm.

3.4. Electron Microscopic Studies

The detailed procedure of fixation and section cutting for scanning and transmission electron microscopy (SEM and TEM, respectively) have been described elsewhere [12].

3.5. Level of MMP Expression

For the study of MMP activity, hepatic tissue was homogenized with phosphate buffer saline (pH 7.4), followed by centrifugation in a cooling centrifuge (REMI, C 24, India). The supernatant was collected and subjected to gelatin zymography [12, 13].

3.6. Statistical Analysis and Scoring of Data

Statistical significance of the difference between experimental groups was calculated using Student's paired t-test [14] for two means. A P <  .05 was considered significant. One way ANOVA has also been performed. The observers were “blinded" if the sample belonged to “experimental" or “control" group at the time of scoring the data.

4. Results

4.1. Biochemical Parameters

Arsenic intoxication caused a significant rise in AST (P <  .05) (Table 1), ALT (P <  .05) (Table 2), AcP (Table 3) and AlkP (Table 4) activity levels in liver and spleen tissues when compared to the control group. The same was true for LPO activity (Table 5). Administration of Ars Alb-200C brought about considerable recuperation in the activities of AST (.05 < P <  .001), AcP, AlkP and ALT (.01 < P <  .001) and also of LPO. There was a palpable reduction in GSH contents of both the tissues in arsenic intoxicated mice (Table 6). These values were significantly increased (.05 < P <  .001) in drug fed mice. Catalase activity (Table 7) significantly declined (.05 < P <  .001) after arsenic trioxide treatment in both the liver and spleen tissues. However, there was a considerable increase of values in the drug fed mice (P <  .001) as compared to that of control. Similarly, both the tissues revealed a substantial depletion (.01 < P <  .001) in the activities of SDH enzyme (Table 7) after repeated arsenic trioxide intoxication. But Ars Alb-200C supplementation produced considerable repletion and the values were comparable to that of controls (both Gr-1 and Gr-3; P <  .001).

Table 1: Mean activities of Aspartate amino transferase (AST) (nM/mg protein/min) in liver and spleen of different series of mice at different fixation intervals.
Table 2: Mean activities of Alanine amino transferase (ALT) (nM/mg protein/min) in liver and spleen of different series of mice at different fixation intervals.
Table 3: Mean activities of Acid phosphatase (AcP) (nM/mg protein/min) in liver and spleen of different series of mice at different fixation intervals.
Table 4: Mean activities of Alkaline phosphatase (AlkP) (nM/100 mg protein/min) in liver and spleen of different series of mice at different fixation intervals.
Table 5: Mean lipid peroxidation (LPO) (nm/MDA/mg wet tissue) in liver and spleen of different series of mice at different fixation intervals.
Table 6: Mean reduced glutathione (GSH) (nm/mg tissue) in liver and spleen of different series of mice at different fixation intervals.
Table 7: Catalase and Succinate dehydrogenase activities in liver and spleen of different series of mice at 90 and 120 days fixation interval.

The SOD levels (Table 8) showed a significant decline in its activity in both liver and spleen tissues after arsenic trioxide treatment. In Ars Alb-200C fed mice, there was considerable revival (P <  .05) and the values were comparable to that of controls. Arsenic intoxication resulted in significant decrease (.05 < P <  .001) of total GRD content in both liver and spleen tissues when compared with normal group. Administration of Ars Alb-200C resulted in significant increase (.05 < P <  .001) in total GRD content (Table 8) in both liver and spleen tissues as compared to arsenic intoxicated group.

Table 8: Glutathione reductase ( mol/mg protein/min) and Superoxide dismutase (unit enzyme/mg protein) in liver and spleen of different series of mice at 90 and 120 days fixation interval.
4.2. Pathological Changes
4.2.1. Blood Hemoglobin

The hemoglobin content was reduced in As2O3 + Alc200 C fed mice as compared to that of normal controls. In Ars Alb-200C fed mice (Table 9), an increase in hemoglobin level was obtained and the values were comparable to that of controls.

Table 9: Mean hemoglobin and Mean Blood sugar (mg/dl) content in different series of mice at different fixation intervals.
4.2.2. Blood Glucose Content

In As2O3 and As2O3 + Alc 200C fed mice, an increase in blood sugar content was observed at successive fixation intervals, the increase being significant (P <  .001) at day 90 only. The increase in blood sugar content (Table 9) was so high that it exceeded the normal level. In Ars Alb-200C fed group, there was also an increase (P <  .001) in blood sugar content except at day 60, where a slight decrease in the said level was observed. Here, the increase was within the permissible limits and not as high as that of As2O3 and As2O3 + alcohol fed group.

4.2.3. Serum Estradiol and Testosterone Concentration

Compared to intoxicated controls (Gr-1), a decrease in serum estradiol and testosterone levels (Table 10) was obtained in As2O3 and As2O3 + Alc200 C fed mice at day 90 and 120. Administration of Ars Alb-200C resulted in an increase in serum estradiol and testosterone levels in comparison to arsenic trioxide treated group.

Table 10: Mean Serum testosterone (ng/mL) and Mean Serum Estradiol (pg/ml) levels in different series of mice at different fixation intervals.
4.3. Transmission Electron Microscopic Study

Contrary to the intact nuclear membrane observed in liver cells of normal (Figure 1(a)) mice and arsenic intoxicated (Figures 1(b)1(d)) mice administered Ars Alb-200C (Figures 1(e)-1(f)), the nuclear membrane in liver cells of As2O3 intoxicated mice seemed to be broken. Destructive changes were prominent in the cristae of arsenic intoxicated mice. Furthermore, number of vacuoles was noticed in arsenic intoxicated mice. Cisternae of the Golgi bodies of arsenic intoxicated mice were absent. In arsenic intoxicated mice fed Ars Alb-200C, these features were less conspicuous.

Figure 1: Representative photomicrographs under TEM of liver sections of normal (a), arsenic intoxicated (b–d) and arsenic intoxicated drug fed mice (e–f). BD, black droplet; ER, endoplasmic reticulum; NM, nuclear membrane; NU, nucleus; WD, white droplet.
4.4. Scanning Electron Microscopic Study

The hepatocytes in normal controls are shown in Figures 2(a) and 2(b). Damaged hepatocytic cells were found in the arsenic intoxicated series (Figure 2(c)). Relatively little damaged hepatocytes were found in the intoxicated group that was fed Ars Alb-200C (Figure 2(d)).

Figure 2: Representative photomicrographs under scanning electron microscopy of liver sections of normal (a–b), arsenic intoxicated (c) and arsenic intoxicated drug fed (d) mice. (Magni- 1KX); H, hepatocyte; MD, mechanical disorder.
4.5. Metalloproteinase Activity

At 90- and 120-day fixation intervals, in As2O3 and As2O3 + Alc 200C fed mice, only one band was expressed near 77 kDa (Figure 3) which presumably belonged to MMP family. However, in some mice, this band was near 97 kDa, presumably belonging to a different MMP member. In the drug fed series, the expression of the single band appeared to be somewhat less.

Figure 3: Gelatin zymogram of liver samples showing the expression of MMP in experimental mice at 120 days l. Lane 1, normal; lane 2, As2O3; lane 3: As2O3 + Alc-200; lane 4, As2O3 + Ars Alb-200; M, molecular weight marker.
4.6. Statistical Analysis

Many of the differences in data revealed by Student's t-test have been found to be statistically significant at different levels, as shown in Tables 110. Similarly, results of one-way ANOVA also revealed significant differences among the different parameters studied (Tables 1113).

Table 11: One way ANOVA for different hepatic enzymes.
Table 12: One way ANOVA of different spleen enzymes.
Table 13: One way ANOVA of blood parameters.

5. Discussion

Arsenic compound is a protoplasmic poison that can bind to human sulphydryl-containing proteins with high affinity. Arsenic trioxide (As2O3), extracted from arsenic compound, is a powerful ancient medication for a variety of ailments with the principle of “using a toxic against another toxic" in traditional Chinese medicine. Strikingly, As2O3 treatment in a regime of 10 mg/day of intravenous infusion for 28–60 days is effective in patients with acute promyelocytic leukemia (APL) without viable toxicity in refractory to the all-trans retinoic acid (ATRA) and the conventional chemotherapy by inducing apoptosis of APL cells [15]. Notably, As2O3 exerts a broader anti-inflammatory activity by inhibition of nuclear factor, NF-κB activation through induction of inhibitor of κ-B expression in the airways [16]. Low dosage of As2O3 may have a potential benefit in treating patients with asthma, especially in those with steroid-dependent and resistant asthma. Overall, existing data suggest a beneficial effect of As2O3 for the treatment of cancer and even inflammatory diseases. However, that even a non-material dose derived from dilution and succussions of As2O3 could show some beneficial effects in the present study is of considerable significance and of some practical application as well. To ascertain the exact amount of arsenic pushed inside the body and simulate a condition of chronic arsenic intoxication, mice were subjected to repeated injections of arsenic trioxide that inflicted hepatic damage and oxidative stress that was observed from a substantial increase in the activities of the hepatic enzymes, namely ALT and AST. An increase in the activity of these marker enzymes portrays possibility of tissue necrosis and loss of functional integrity of hepatocyte membrane. Reduction in the levels of ALT and AST towards the respective normal values by administration of Ars Alb-200C is an indication of the protective ability of the potentized homeopathic drug as well as its ability to repair hepatic tissue damage inflicted by As2O3. During hepatic injury, superoxide radicals are known to be generated at the site of damage, which in turn modulate activities of SOD and CAT, resulting in the loss of activity and accumulation of superoxide radical, which are responsible for damage of liver tissue. Decreased CAT activity is linked to the exhaustion of the enzyme as a result of oxidative stress caused by As2O3. SOD and CAT activities were brought down to near normal after treatment with Ars Alb-200C. This gives a positive indication regarding the protective efficacy of the potentized homeopathic drug.

Reduced glutathione (GSH) constitutes the first line of defense against free radicals. It plays an important role in the regulation of cell proliferation and cellular defense [17]. Exposure of cells to arsenic trioxide leads to the depletion of GSH, which may also signify damage to the hepatic cells. Positive alterations in endogenous GSH have been encountered in the present investigation after administration of the homeopathic remedy, which is in line with the activities of other biomarkers. The availability of sufficient amount of GSH increased the detoxification of active metabolites of As2O3. Succinate dehydrogenase is a membrane-bound dehydrogenase linked to the respiratory chain and is a member of the Krebs’ cycle [18]. Positive modulations encountered in the activity of this enzyme and those of SOD and CAT in the drug fed mice lends support to the protective ability of the remedy in cellular and sub-cellular environments. GSSG is reduced to GSH by glutathione reductase, which is NADPH-dependent. It plays a significant role in maintaining adequate amounts of GSH. Accordingly, the reduction of GRD results in decreasing GSH [18]. In As2O3 treated mice, the activity of GRD is markedly decreased. An increase in GRD activity highlights the hepato-protective ability of the remedy.

Elevated blood glucose levels in As2O3 and As2O3 + alcohol fed mice was also considerably reduced in the drug fed series. The level of blood hemoglobin was markedly decreased in arsenic intoxicated group, but in the drug fed mice the level slightly increased. Similarly, serum estradiol and testosterone levels decreased markedly in arsenic trioxide injected mice. Testosterone, an anabolic steroid, is responsible for the development and maintenance of male secondary sex characters as well as growth promoting effects. Decreased testosterone levels in males may indicate hypothalamic or pituitary disorders or damage to the testis. Alternatively, decrease in the level of serum testosterone could also be implicated to a direct relationship with the increase in toxicity due to arsenic intoxication. A positive correlation can be drawn between increased SHA and an increase in testosterone level. Positive changes in the levels of these hormones were encountered in the drug fed mice. Eagon et al. [19] showed an increased level of estradiol in females of a rat model of hyperplasia.

An increase in the number of mitochondria, distorted nuclei and large black lipid droplets was observed in TEM study of liver tissues of arsenic treated mice. Similarly, in SEM study, damaged hepatocytes and hepatic chords were observed in arsenic intoxicated group. In the drug fed series, however, these features were less marked, which would also support the positive effects of the drug in ameliorating arsenic induced effect at the ultrastructural level. MMPs hydrolyze components of the extracellular matrices; these proteases play a central role in many biological processes. MMPs facilitate invasion and metastization of carcinoma cells [20]. MMPs are a family of Zn2+- and Ca2+-dependent endopeptidases secreted by both normal and transformed cells, and capable of degrading collagenous and non-collagenous components of extracellular matrix [21, 22]. Results of the present study revealed a high level of expression of metalloproteinases. This is in conformity with high levels of expression of metalloproteinases reported in pathological conditions such as wound healing, angiogenesis, tumor invasion, metastasis [2326], arthritis, emphysema and apoptosis [27, 28]. In the drug fed mice, no overexpression of metalloproteinases was noticed. Therefore, the expression of MMPs or rather the lack of expression provides substantial evidence in favor of their anti-tumorigenic effects at the gene expression level.

How the ultra low doses of the potentized remedy could bring about multiple changes in both enzymatic and pathological parameters as well as many biomarkers is rather unclear at the present state of our knowledge. Incidentally, Khuda-Bukhsh [2932] proposed a working hypothesis that one mechanism through which the potentized homeopathic drugs act could be through regulation of expression of certain relevant genes. This explanation seems plausible because all the biomarkers tested are regulated by specific genetic regulatory mechanisms, and without involvement of these regulatory mechanisms, such positive results could not have been achieved.

6. Conclusion

The results of the present study suggests that Arsenicum Album 200C can be used as an interim relief measure, especially in high-risk arsenic contaminated areas, at least till arsenic-free drinking water or better strategies to manage this dreadful problem are available. However, this would need further clinical trial, preferably by others, to validate the ameliorative potentials for its homeopathic use in large scale in the arsenic contaminated areas.


A research grant from Boiron Lab, Lyon, France to Prof. A. R. Khuda Bukhsh is gratefully acknowledged. The authors are thankful to Dr T.C. Nag, AIIMS, New Delhi for providing necessary infrastructural support and expertise for electron microscopic studies.


  1. E. García-Chávez, A. Santamaría, F. Díaz-Barriga, P. Mandeville, B. I. Juárez, and M. E. Jiménez-Capdeville, “Arsenite-induced formation of hydroxyl radical in the striatum of awake rats,” Brain Research, vol. 976, no. 1, pp. 82–89, 2003. View at Publisher · View at Google Scholar
  2. J. Pi, H. Yamauchi, Y. Kumagai et al., “Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water,” Environmental Health Perspectives, vol. 110, no. 4, pp. 331–336, 2002.
  3. S. Ahmad, K. T. Kitchin, and W. R. Cullen, “Arsenic species that cause release of iron from ferritin and generation of activated oxygen,” Archives of Biochemistry and Biophysics, vol. 382, no. 2, pp. 195–202, 2000. View at Publisher · View at Google Scholar · View at PubMed
  4. H. U. Bergmeyer and E. Brent, “Aminotransferases,” in Methods of Enzymatic Analysis, H. U. Bergmeyer, Ed., pp. 735–760, Verlag Chemie Weinheim. Academic Press, New York, NY, USA, 1974.
  5. G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959.
  6. B. Chance and A. C. Maehly, “Assay of catalase and peroxidase,” Methods in Enzymol, vol. 2, pp. 764–775, 1955.
  7. P. Kakkar, B. Das, and P. N. Viswanathan, “A modified spectrophotometric assay of superoxide dismutase,” Indian Journal of Biochemistry and Biophysics, vol. 21, no. 2, pp. 130–132, 1984.
  8. E. C. Slater and W. D. Bonner, “The effect of fluoride on succinic oxidase system,” Biochemical Journal, vol. 52, pp. 185–196, 1952.
  9. I. Carlberg and B. Mannervik, “Glutathione reductase levels in rat brain,” The Journal of Biological Chemistry, vol. 250, no. 14, pp. 5475–5480, 1975.
  10. J. Mohandas, J. J. Marshall, G. G. Duggin, J. S. Horvath, and D. Tiller, “Differential distribution of glutathione and glutathione related enzymes in rabbit kidney: possible interactions in analgesic neuropathy,” Cancer Research, vol. 44, pp. 5086–5091, 1984.
  11. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with Folin-Phenol reagent,” The Journal of Biological Chemistry, vol. 193, pp. 265–275, 1951.
  12. S. Pathak and A. R. Khuda-Bukhsh, “Assessment of hepatocellular damage and hematological alterations in mice chronically fed p-dimethylaminoazobenzene and phenobarbital,” Experimental and Molecular Pathology, vol. 83, pp. 104–111, 2007.
  13. P. C. Billings, J. M. Habres, D. C. Liao, and S. W. Tuttle, “Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor,” Cancer Research, vol. 51, no. 20, pp. 5539–5543, 1991.
  14. R. A. Fisher and F. Yates, Statistical Tables for Biological, Agricultural and Medical Research, Oliver and Boyd, Edinburgh, UK, 6th edition, 1963.
  15. P.-Z. Zheng, K.-K. Wang, Q.-Y. Zhang et al., “Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation apoptosis of promyelocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7653–7658, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. L. F. Zhou, Y. Zhu, X. F. Cui, W. P. Xie, A. H. Hu, and K. S. Yin, “Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation,” Respiratory Research, vol. 7, p. 146, 2006.
  17. S. Karasaki, “Cell proliferation and subcellular localization of alkaline phosphatase activity in rat liver parenchyma during azo dye induced carcinogenesis,” Cancer Research, vol. 35, pp. 482–491, 1975.
  18. R. O. Recknagel, E. A. Glende, and R. S. Britton, “Free radical damage and lipid peroxidation,” in Hepatotoxicology, R. G. Meeks, S. D. Harrison, and R. J. Bull, Eds., pp. 401–436, CRC Press, Boca Raton, Fla, USA, 1991.
  19. P. K. Eagon, N. Chandar, M. J. Epley, M. S. Elm, E. P. Brady, and K. N. Rao, “Di(2-ethylhexyl)phthalate-induced changes in liver estrogen metabolism and hyperplasia,” International Journal of Cancer, vol. 58, no. 5, pp. 736–743, 1994.
  20. M. J. Heslin, J. Yan, M. R. Johnson, H. Weiss, R. B. Diasio, and M. M. Urist, “Role of matrix metalloproteinases in colorectal carcinogenesis,” Annals of Surgery, vol. 233, no. 6, pp. 786–792, 2001. View at Publisher · View at Google Scholar
  21. L. A. Liotta, P. S. Steeg, and W. G. Stetler-Stevenson, “Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation,” Cell, vol. 64, no. 2, pp. 327–336, 1991.
  22. L. M. Matrisian, “Metalloproteinases and their inhibitors in matrix remodeling (Review),” Trends in Genetics, vol. 6, pp. 121–125, 1990.
  23. J. F. Woessner Jr., “Matrix metalloproteinases and their inhibitors in connective tissue remodeling,” The FASEB Journal, vol. 5, no. 8, pp. 2145–2154, 1991.
  24. A. Y. Lee, K. T. Akers, M. Collier, L. Li, A. Z. Eisen, and J. L. Seltzer, “Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4424–4429, 1997. View at Publisher · View at Google Scholar
  25. J. L. Seltzer, A. Y. Lee, K. Y. Akers, and M. Collier, “Activation of 72- kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction,” Experimental Cell Research, vol. 213, pp. 365–374, 1994.
  26. H. Birkedal-Hansen, “Proteolytic remodeling of extracellular matrix,” Current Opinion in Cell Biology, vol. 7, no. 5, pp. 728–735, 1995. View at Publisher · View at Google Scholar
  27. J. M. Ray and W. G. Stetler-Stevenson, “The role of matrix metalloproteases and their inhibitors in tissue invasion, metastasis and angiogenesis,” The European Respiratory Journal, vol. 7, pp. 2062–2072, 1994.
  28. Z. Wang, R. Juttermann, and P. D. Soloway, “TIMP-2 is required for efficient activation of proMMP-2 in vivo,” The Journal of Biological Chemistry, vol. 275, no. 34, pp. 26411–26415, 2000. View at Publisher · View at Google Scholar · View at PubMed
  29. A. R. Khuda-Bukhsh, “Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo,” Complementary Therapies in Medicine, vol. 5, pp. 43–46, 1997.
  30. A. R. Khuda-Bukhsh, “Towards understanding molecular mechanisms of action of homeopathic drugs: an overview,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 339–345, 2003. View at Publisher · View at Google Scholar
  31. A. R. Khuda-Bukhsh, J. R. Moffett, P. Arun, and M. A. A. Namboodiri, “Laboratory research in homeopathy: pro,” Integrative Cancer Therapies, vol. 5, no. 4, pp. 320–342, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. A. R. Khuda-Bukhsh and S. Pathak, “Homeopathic drug discovery: theory update and methodological aspect,” Expert Opinion on Drug Discovery, vol. 3, no. 8, pp. 979–990, 2008. View at Publisher · View at Google Scholar